Heparin-induced thrombocytopenia in medical surgical critical illness

Chest

Volumn 144, Issue 3, 2013, Pages 848-858

  Warkentin, Theodore E ^a   Sheppard, Jo Ann I ^a   Heels Ansdell, Diane ^b   Marshall, John C ^d   McIntyre, Lauralyn ^f   Rocha, Marcelo G ^j   Mehta, Sangeeta ^e   Davies, Andrew R ^m   Bersten, Andrew D ⁿ   Crozier, Tim M ^k   Ernest, David ^l   Vlahakis, Nicholas E ^o   Hall, Richard I ^g   Wood, Gordon G ^h   Poirier, Germain ⁱ   Crowther, Mark A ^c   Cook, Deborah J ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h VANCOUVER ISLAND HEALTH AUTHORITY   (Canada)

ⁱ HÔPITAL CHARLES LEMOYNE   (Canada)

^j Pavilhão Pereira Filho Hospital   (Brazil)

^k MONASH MEDICAL CENTRE   (Australia)

^l MONASH UNIVERSITY   (Australia)

^m ALFRED HOSPITAL   (Australia)

ⁿ FLINDERS UNIVERSITY   (Australia)

^o MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; HEPARIN; IMMUNOGLOBULIN G ANTIBODY;

ADULT; AGED; ANAPHYLAXIS; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; CRITICAL ILLNESS; DEATH; DEEP VEIN THROMBOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE UNIT; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

EID: 84884321139     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-0057     Document Type: Article

References (31)

1. Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH ; Scientifi c and Standardization Committee of the International Society on Thrombosis and Haemostasis. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost. 2011 ; 9 (12): 2498-2500.
2. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005; 106(8): 2710-2715.
3. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006 ; 108 (9): 2937-2941.
4. National Institutes of Health Clinical Center. Prophylaxis for thromboembolism in critical care trial (PROTECT). NCT00182143. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2005. http://clinicaltrials.gov/ct2/show/NCT00182143. Updated January 7, 2011.
5. Cook D, Meade M, Guyatt G, et al; PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011 ; 364 (14): 1305-1314.
6. Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf. 2009 ; 8 (2): 129-144.
7. Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal profi le of the anti-PF4/heparin immune response. Blood. 2009 ; 113 (20): 4970-4976.
8. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost. 2011 ; 9 (suppl 1): 105-117.
9. Cook D, Meade M, Guyatt G, et al PROphylaxis for Thrombo-Embolism in Critical Care Trial protocol and analysis plan. J Crit Care. 2011 ;26(2):223.e1-e9.
10. Crowther MA, Cook DJ, Albert M, et al; Canadian Critical Care Trials Group. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care. 2010 ; 25 (2): 287-293.
11. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparininduced thrombocytopenia. Blood. 1986 ; 67 (1): 27-30.
12. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measure ments using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008 ; 6 (8): 1304-1312.
13. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000; 96 (5): 1703-1708.
14. Warkentin TE, Sheppard JI, Moore JC, Kelton JG. The use of well-characterized sera for the assessment of new diagnostic enzyme-immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2010 ; 8 (1): 216-218.
15. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006 ; 4 (4): 759-765.
16. Warkentin TE. Think of HIT. Hematology (Am Soc Hematol Educ Program). 2006 ; 408-414.
17. Warkentin TE, Cook RJ, Marder VJ, Greinacher A. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost. 2010 ; 8 (3): 504-512.
18. Finfer S, Chittock DR, Su SY, et al ; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 ; 360 (13): 1283-1297.
19. Verma AK, Levine M, Shalansky SJ, Carter CJ, Kelton JG. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy. 2003 ;23(6):745-753.
20. Crowther MA, Cook DJ, Meade MO, et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care. 2005 ; 20 (4): 348-353.
21. Trehel-Tursis V, Louvain-Quintard V, Zarrouki Y, Imbert A, Doubine S, Stéphan F. Clinical and biologic features of patients suspected or confi rmed to have heparin-induced thrombocytopenia in a cardiothoracic surgical ICU. Chest. 2012; 142(4): 837-844.
22. Warkentin TE, Kelton JG. Temporal aspects of heparininduced thrombocytopenia. N Engl J Med. 2001 ; 344 (17): 1286-1292.
23. Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparininduced thrombocytopenia confi rmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011 ; 9 (12): 2389-2396.
24. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003 ; 121 (4): 535-555.
25. Gruel Y, Pouplard C, Nguyen P, et al; French Heparin-Induced Thrombocytopenia Study Group. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol. 2003 ; 121 (5): 786-792.
26. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecularweight heparin or unfractionated heparin. N Engl J Med. 1995 ; 332 (20): 1330-1335.
27. Greinacher A, Eichler P, Lietz T, Warkentin TE. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood. 2005; 106 (8): 2921-2922.
28. Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood. 2010 ; 115 (9): 1797-1803.
29. Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med. 2007 ; 35 (4): 1165-1176.
30. Ansell JE, Clark WP Jr, Compton CC. Fatal reactions associated with intravenous heparin. Drug Intell Clin Pharm. 1986 ; 20 (1): 74-75.
31. Mims MP, Manian P, Rice L. Acute cardiorespiratory collapse from heparin: a consequence of heparin-induced thrombocytopenia . Eur J Haematol. 2004 ; 72 (5): 366-369.